European Platform for Neurodegenerative Diseases

New European initiative will build a collaborative platform for data and sample sharing, to accelerate the discovery and validation of biomarkers for neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD).

• EPND will become a future European infrastructure, facilitating access to biological samples and data to accelerate biomarker discovery and validation and eventually support the development of therapeutics for neurodegenerative diseases.

For more please visit www.epnd.org

 

• The European Platform for Neurodegenerative Diseases (EPND) integrates existing initiatives to build, grow, and deliver a scalable and self-sustainable platform for storage and analysis of high-quality clinical samples and data collections.
• EPND is a public-private partnership funded by the Innovative Medicines Initiative (IMI), a Joint Undertaking between the EU and European pharmaceutical industries that supports projects at the vanguard of health research.

EPND will bring together 29 partners from the public and private sectors and will be managed by two public partners, University of Maastricht and University of Leicester, and two private partners, Gates Ventures and UCB Biopharma. EPND will leverage and connect existing European research infrastructures, including BBMRI, EATRIS, ELIXIR and EBRAINS.